Paradigm Shift for Thrombolysis for Patients with Acute Ischaemic Stroke, from Extension of the Time Window to the Rapid Recanalisation After Symptom Onset - European Medical Journal


Paradigm Shift for Thrombolysis for Patients with Acute Ischaemic Stroke, from Extension of the Time Window to the Rapid Recanalisation After Symptom Onset

| Download as | PDF
11 Mins
Hye Seon Jeong, *Jei Kim

The authors have declared no conflicts of interest.

EMJ. ;2[2]:98-103.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Intravenous thrombolysis (IVT) and intra-arterial thrombolysis (IAT) are useful therapeutic tools to improve functional outcomes after recanalisation of occluded vessels in patients with acute ischaemic stroke. IVT could be performed for more patients by extending the time interval to 4.5 hours from onset to IVT initiation; however, this does not significantly improve functional outcomes. Recent studies indicated that IAT, particularly intra-arterial thrombectomy (IA-thrombectomy), significantly improved functional outcomes after recanalisation of occluded vessels, particularly when the recanalisation was performed within 6 hours of symptom onset. The focus of thrombolysis for acute ischaemic stroke patients is changing from extending the time window for IVT to successfully achieving good functional outcomes with IA-thrombectomy, by performing it within the 6-hour time limit. In this review, we discuss the present status of and limitations of extending IA-thrombectomy for improved functional outcomes after thrombolysis.


Thrombolysis, within the appropriate therapeutic window, is an essential tool that should be considered for patients with acute ischaemic stroke. Intravenous thrombolysis (IVT) has been considered as a primary thrombolysis for these patients.1 Recently, the time frame for which IVT is effective has been extended from <3 to 4.5 hours from symptom onset to the administration of intravenous thrombolytic agent.2,3 However, when IVT is performed for acute ischaemic stroke within the extended time period, functional outcomes are not always significantly improved.2,4

Intra-arterial thrombolysis (IAT) has been used as a bridging therapy after IVT failure or as primary thrombolysis within a 6-hour window for patients with acute ischaemic stroke.5 A higher recanalisation rate has been reported with IAT than with IVT alone.5 Furthermore, compared with IVT or IAT using thrombolytic agents, significantly better functional outcomes and recanalisation rates have recently been achieved with the direct removal of the thrombus using intra-arterial thrombectomy (IA-thrombectomy) in acute ischaemic stroke patients.6-10

After the recent successes with IA-thrombectomy, it immediately became the thrombolytic tool of choice when performed within the therapeutic window.11,12 However, IVT is still recommended as the primary thrombolytic method for acute stroke patients, even if endovascular treatments are being considered, as this delivers high recanalisation rates and better clinical outcomes.13 IAT as the primary or bridging therapeutic option has several barriers to its nationwide or global use, such as medical cost, limited availability of modern imaging tools, and experienced personnel.14,15 Here, we review the present status of thrombolysis and the benefits and limitations of IA-thrombectomy to achieve successful functional outcomes after thrombolysis in patients with acute ischaemic stroke.


IVT can be rapidly initiated after confirmation of the inclusion criteria and time since onset for acute stroke patients.1,3 Following the publication of the National Institute of Neurological Disorders and Stroke (NINDS) trial for IVT,1 the appropriate dose and extension of the time window have been sought, primarily to decrease the haemorrhagic side effects and increase the number of patients who benefit from IVT.

Efforts to Change Dose of Thrombolytic Agent for Intravenous Thrombolysis

The recommended standard dose of tissue plasminogen activator (tPA) for IVT is 0.9 mg/kg body weight (maximum 90 mg); administration should be a bolus injection of 10% of the calculated dose, followed by administration of the remaining 90% of the dose at a constant rate over 60 minutes.1 In previous Asian studies, a lower dose of 0.6 mg/kg tPA was evaluated for safety and to determine if it could achieve the same efficacy as the 0.9 mg/kg dose.16 This low-dose tPA, when initiated within 4.5 hours, had comparable effectiveness and safety as with the standard dose in South Korean stroke patients.17 However, the efficacy and safety of low-dose tPA need to be evaluated in a controlled trial.18 The ENCHANTED trial, which is a randomised controlled trial to evaluate low-dose tPA, recently completed recruitment.19

Changes in the Time Window for Intravenous Thrombolysis

Rapid recanalisation of the occluded intracranial artery is an important factor in achieving good clinical outcome after thrombolysis for acute ischaemic stroke patients.20,21 However, extending the time window for IVT from 3 to 4.5 hours was another important attempt to increase the number of acute ischaemic stroke patients eligible to receive thrombolysis. After the suggestion to extend the time window to >3 hours,22 the safety and clinical outcomes of IVT performed within 4.5 hours were similar to those within 3 hours in randomised trials including the SITS-ISTR23 and ECASSIII3 trials. Extension of the time window to up to 6 hours for IVT was suggested in acute ischaemic stroke patients with penumbral area evaluated diffusion and perfusion mismatch on magnetic resonance imaging.24,25 Even though subsequent studies showed the functional benefits of extension of the time window up to 4.5 hours for IVT,26 further studies are necessary to verify the safety and efficacy of this change.27,28 The 4.5-hour time window for IVT is recommended in the 2015 American Heart Association/American Stroke Association (AHA/ASA) guideline for acute ischaemic stroke patients.13


Compared with IVT, IAT and particularly IA-thrombectomy using advanced interventional devices could achieve recanalisation more reliably and lead to better functional outcomes for acute stroke patients.5,12 In the updated guidelines for IAT, the primary changes involve the devices used, and, time point for bridging or primary thrombolysis.13

Changes in the Thrombolytic Devices for Intra-Arterial Thrombolysis

After a successful randomised trial of direct intra-arterial injection of thrombolytic agents,29 thrombolytic tools for IAT subsequently advanced to mechanical disruption30,31 and recently to direct removal of the thrombus using retrievable stents32,33 and suction devices.34 With the advances in the IAT tools, the recanalisation rate significantly improved from >60% with direct injection5 to >80% with direct removal.35 Ultimately, IA-thrombectomy using stent retrievers was recommended over direct intra-arterial injection as the primary IAT for acute stroke patients in the 2015 AHA/ASA guideline.13

Unlike IVT, the recanalisation status of the occluded vessels can be confirmed after IAT. Therefore, the time interval from onset-to-recanalisation (OTR) as well as the onset-to-treatment (OTT) time can be evaluated during IAT, including IA-thrombectomy. In the analysis of the functional outcomes following IAT, the OTT criteria of <6 hours was used. However, OTR is frequently >6 hours because IAT interventions usually take several hours to complete. Although knowledge of OTT is useful to understand how quickly IAT is initiated, OTR is a better indicator of the start of reperfusion in the infarcted area. Therefore, to evaluate the benefits of IAT, including IA-thrombectomy, OTR might be more useful than OTT.

Three well-known studies that used only OTT to analyse functional outcomes after IAT failed to determine a benefit for these outcomes in acute ischaemic stroke patients.36-38 However, five pivotal studies that were subsequently conducted reported that good functional outcomes were achieved significantly more often in patients for whom OTR was within 6 hours.6-10 Another study looking at IA-thrombectomy, showed better functional outcomes (determined by a modified Rankin score 0-2) when OTR was <6 hours.39 Evidence shows that rapid recanalisation, defined as a 6-hour time limit for OTR, was more important than rapid initiation of IAT, defined as a 6-hour time window for OTT, to achieve a good post-IAT functional outcome. In the 2015 AHA/ASA guidelines, a 6-hour time window for OTT is recommended for IAT, including IA-thrombectomy, as bridging or primary thrombolysis in patients who have a contraindication for IVT.13 However, the 6-hour time limit for OTR should be considered for the successful achievement of functional outcomes after IAT intervention forfuture acute ischaemic stroke patients.

Bridging Intra-Arterial Thrombolysis After Intravenous Thrombolysis Failure

Although rapid IVT within a 4.5-hour time window is recommended as the primary thrombolysis for acute ischaemic stroke patients with large artery occlusion, the rates of recanalisation and good functional outcome after IVT are <27%40,41 and <40%, respectively.5 Bridging IAT within a 6-hour time window has been attempted after a failed initial IVT and achieved a higher recanalisation rate of approximately 60%.5 Unfortunately, a previous randomised study failed to show clinical benefits in patients who underwent bridging IA-thrombectomy within the 6-hour OTT time window.36 However, another randomised bridging study that achieved OTR within 6 hours observed a significant improvement in the functional outcome in patients who underwent bridging IA-thrombectomy.7 Now, IA-thrombectomy is recommended for bridging after unsuccessful IVT or primary therapy within a 6-hour time frame for OTT.13


A 6-hour time limit for OTR, rather than the time frame for OTT, is an important factor for a good functional outcome in patients undergoing IAT. In addition to the OTR time limit, three types of factors are related with a good functional outcome after IAT: patient-related, infarction severity-related, and procedure-related factors.

Patient-Related Factors

Patient-related factors that are associated with prognosis or increased haemorrhagic risk with IVT42,43 and with functional outcome with IA-thrombectomy7,44,45 include older age, presence of cardiovascular risk factors, and presence of comorbid diseases before the start of thrombolysis. Atrial fibrillation might be an independent factor for functional outcome with IAT, including IA-thrombectomy.46 Intra-cerebral haemodynamic alterations47 caused by systemic haemodynamic changes has been shown in patients with atrial fibrillation.48 Altered intra-cerebral haemodynamic status in patients with atrial fibrillation could decrease the blood flow in the occluded hemisphere.47 Ultimately, clinical outcomes following acute ischaemic stroke may be worse in patients with co-morbid atrial fibrillation compared to those without this condition.46 In addition, age-related vessel changes such as vascular tortuosity, distortion of the aortic arch and aorta, and high atherosclerotic burden inside the vessels delay catheter arrival to the thrombus and cause intervention-related infarctions in elderly patients.49

Infarction Severity-Related Factors

Infarction severity-related factors include the initial clinical and radiological status before IAT. A high National Institutes of Health Stroke Score,45,50 low Alberta Stroke Program Early Computed Tomography score,45,46 extensive (>8 mm) clot burden,46 and terminal ICA occlusion39 on initial imaging are prognostic factors that correlate with poor functional outcome after IAT. The presence of collateral support to the ischaemic lesion on pre-intervention angiography is useful prognostically as it suggests there will be less infarct growth. Good collaterals to the ischaemic lesion are independently related with early improvement in functional outcome after IAT.46 Furthermore, good collateral circulation to the ischaemic lesion is related with a higher recanalisation rate, shorter recanalisation time, and fewer haemorrhagic complications after IAT.52-54

Procedure-Related Factors

Procedure-related factors include recanalisation grade and development of haemorrhagic complications after IAT as well as the use of advanced intervention tools and shortened time intervals from symptom onset to recanalisation. As already discussed, using retractable stents and/or suction devices markedly increase the recanalisation rate with IAT. General anaesthesia with intubation and conscious sedation has been used for acute ischaemic stroke patients receiving endovascular therapy.55 Even though the individualised selection of conscious sedation and general anaesthesia was recommended during endovascular therapy in the 2015 AHA/ASA guideline,13 randomised trial data are still needed to determine the anaesthesia technique for endovascular treatment. In addition, shortened OTRs are related to enhanced functional outcomes after IAT. In previous studies, a successful recanalisation grade was useful for predicting a good functional outcome5,56 and severe  haemorrhagic complications were associated with poor post-IAT outcomes.57 However, in other previous studies, although the recanalisation grade and haemorrhagic complications were correlated with clinical outcomes after IAT and IA-thrombectomy in univariate analysis, these two factors were not related with functional outcomes in the multivariate analysis.39,46


Although the five recent pivotal IA-thrombectomy studies showed the importance of a 6-hour OTR time limit to achieve a good functional outcome for patients with acute ischaemic stroke, it is not easy to quickly disseminate the practice of IA-thrombectomy nationwide in many countries.

One primary reason for this difficulty is the need to establish comprehensive stroke centres, in which experienced personnel and the critical pathway, including angiographic tools, are available 24/7. This is necessary to achieve the 6-hour OTR for recanalisation of the occluded vessels using IA-thrombectomy. These centres have been established in the USA and several European countries.58,59 However, in other, particularly developing countries, the nationwide extension of comprehensive stroke centres might be limited by the availability of local expertise and economic support. Government initiatives could support a model to rapidly establish comprehensive stroke centres, as in South Korea.60

Another primary issue is extension of IA-thrombectomy to more rural areas of a country that only have primary stroke centres or local hospitals. In rural primary stroke centres it might only be possible to start IVT for acute ischaemic stroke patients. Therefore, for patients living in these areas, a transfer network for bridging IVT/IA-thrombectomy is needed, with IVT performed first in a primary stroke centre, followed by IA-thrombectomy in a comprehensive stroke centre within the OTR time limit. The transfer network between local hospital and primary and comprehensive stroke centres might be the most important component for extending IA-thrombectomy to rural areas in the near future.


For patients with acute ischaemic stroke, IVT is recommended as primary thrombolysis within a 4.5-hour OTT time window.13 However, the rate of a good functional outcome, namely independent ambulation at discharge, remains at approximately 33% despite an extended time window of 4.5 hours.4 Therefore IA-thrombectomy is recommended, within a 6-hour time window, as a bridge after IVT failure, and primary thrombolysis in patients who are contraindicated for IVT.13 IA-thrombectomy increases the overall rate of good functional outcomes to 47% for patients who undergo IAT within the 6-hour OTT time window and to 66% for patients who are re-canalised within the 6-hour OTR time limit after IAT.39

To date, there has been a lot of interest in increasing the probability of thrombolysis by extending the time window for acute stroke patients. Given the recent pivotal studies of IA-thrombectomy, attention should be given to increasing the probability of good functional outcomes. Now, we should try to start IVT within the extended 4.5-hour OTT time window. In addition, we need to increase the chance of IA-thrombectomy for acute intracranial large artery occlusion withinthe 6-hour OTR time limit to achieve good post-IAT functional outcomes, despite the barriers that exist in real-life settings.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-7. Wardlaw JM et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet. 2012;379:2364-72. Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-29. Saver JL et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-8. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: A meta-analysis. Stroke. 2007;38(3):967-73. Campbell BC et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11);1009-18. Goyal M et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-30. Saver JL et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285-95. Jovin TG et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-306. Berkhemer OA et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20. Ding D. Endovascular mechanical thrombectomy for acute ischemic stroke: A new standard of care. J Stroke. 2015;17(2):123-6. Balasubramaian A et al. Evolution of endovascular therapy in acute stroke: Implications of device development. J Stroke. 2015;17(2):127-37. Powers WJ et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: Guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020-35. Kim JS. Endovascular therapy: A standard treatment? J Stroke. 2015;17(2):93. Tatlisumak T. Implication of the recent positive endovascular intervention trials for organizing acute stroke care: European perspective. Stroke. 2015;46(6):1468-73. Mori E et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 2010;41(3):461-5. Kim BJ et al. Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: A comparative effectiveness and safety study. Stroke. 2015;46(9):2541-8. Ng KW, Sharma VK. Low-dose versus standard-dose tissue plasminogen activator for intravenous thrombolysis in Asian acute ischemic stroke patients. Stroke. 2010;41(8):e545-6. Anderson CS et al. Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED). Int J Stroke. 2015;10(8):1313-5. Khatri P et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73(13):1066-72. Yeo LL et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol. 2013;70(3):353-8. Hacke W et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-74. Wahlgren N et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet. 2008;372(9646):1303-9. Davis SM et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol. 2008; 7(4):299-309. Olivot JM et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke. 2008; 39(8):2257-63. Yeo LL et al. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22(8):e590-6. Wechsler LR. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established. Stroke. 2014;45(3):914-5. Fisher M, Hachinski V. European Cooperative Acute Stroke Study III: support for and questions about a truly emerging therapy. Stroke. 2009;40(6):2262-3. Furlan A et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282(21):2003-11. Noser EA et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke 2005;36(2):292-6. Sorimachi T et al. Recanalization by mechanical embolus disruption during intra-arterial thrombolysis in the carotid territory. AJNR Am J Neuroradiol 2004;25(8):1391-402. Smith WS et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke. 2008;39:1205-12. Flint AC et al. Mechanical thrombectomy of intracranial internal carotid occlusion: Pooled results of the MERCI and Multi MERCI Part I trials. Stroke. 2007;38(4):1274-80. Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40(8):2761-8. Hong KS et al. Endovascular recanalization therapy in acute ischemic stroke: Updated meta-analysis of randomized controlled trials. J Stroke. 2015;17(3):268-81. Broderick JP et al.; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903. Ciccone A et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(25):2433-4. Kidwell CS et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914-23. Jeong HS et al. Impacts of rapid recanalization and collateral circulation on clinical outcome after intraarterial thrombolysis. J Stroke. 2015;17(1):76-83. Lee KY et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke. 2007;38(1):192-3. Bhatia R et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action. Stroke. 2010;41(10):2254-8. Strbian D et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: The DRAGON score. Neurology. 2012;78(6):427-32. Strbian D et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71(5):634-41. Castonguay AC et al. Influence of age on clinical and revascularization outcomes in the North American Solitaire Stent-Retriever Acute Stroke Registry. Stroke. 2014;45(12):3631-6. Raoult H et al. Prognostic factors for outcomes after mechanical thrombectomy with solitaire stent. J Neuroradiol. 2013;40(4):252-9. Jeong HS et al. Predictive factors for early clinical improvement after intra-arterial thrombolytic therapy in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(4):e283-9. Lavy S et al. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke. 1980;11(1):35-8. Abildskov JA et al. Atrial fibrillation. Am J Cardiol. 1971;28(3):263-7. Ribo M et al. Difficult catheter access to the occluded vessel during endovascular treatment of acute ischemic stroke is associated with worse clinical outcome. J Neurointervent Surg. 2013;5 Suppl 1:i70-3. Kurre W et al. Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged ≥80 years. Cerebrovasc Dis. 2013;36(5-6):430-6. Kamalian S et al. Clot length distribution and predictors in anterior circulation stroke: Implications for IA therapy. Stroke. 2013;44(12):3553-6. Marks MP et al. Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke. Stroke. 2014;45(4):1035-9. Liebeskind DS et al. Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014;45(3):759-64. Bang OY et al. Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke. 2011;42(3):693-9. Anastasian ZH. Anaesthetic management of the patient with acute ischaemic stroke. Br J Anaesth. 2014;113(suppl 2):ii9-16. Mazighi M et al. Dramatic recovery in acute ischemic stroke is associated with arterial recanalization grade and speed. Stroke. 2012;43(11):2998-3002. Khatri P et al. Intracranial hemorrhage associated with revascularization therapies. Stroke. 2007;38(2):431-40. Gorelick PB. Primary and comprehensive stroke centers: history, value and certification criteria. J Stroke. 2013;15(2):78-89. Leys D et al. Facilities available in European hospitals treating stroke patients. Stroke. 2007;38(11):2985-91. Kim J et al. Establishment of government-initiated comprehensive stroke centers for acute ischemic stroke management in South Korea. Stroke. 2014;45(8):2391-6.